Reported about 1 year ago
Exact Sciences, a cancer-focused biotech company, has seen its stock price drop by 41% this year. Despite this, Cathie Wood's investment firm, Ark Invest, and analysts on Wall Street have not lost faith in the company, setting an average price target of $83.46, indicating a potential 93% upside. Exact Sciences is known for its innovative cancer diagnostic tests, with its flagship product Cologuard facing competition from Guardant Health. While the company is working on new products, including a next-gen Cologuard, it is unlikely to reach the 93% price target within the next 12 months. However, the company's focus on cost reduction, improved margins, and innovative product development could provide long-term investment opportunities.
Source: YAHOO